Patents by Inventor Shiyong FAN

Shiyong FAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230303494
    Abstract: The present invention relates to a benzylamine derivative, a preparation method therefor and use thereof, and in particular, to a benzylamine derivative as represented by general formula (I), or a pharmaceutically acceptable stereoisomer, salt, solvate or prodrug thereof, which has a strong binding capability with human PD-L1, can obviously inhibit the interaction of PD-1/PD-L1, and has significant anti-tumor efficacy in vivo. Therefore, the present invention also relates to a preparation method for the benzylamine derivative and use thereof in preparing a drug for treating PD-1/PD-L1-related diseases.
    Type: Application
    Filed: July 28, 2021
    Publication date: September 28, 2023
    Inventors: Junhai XIAO, Song LI, Jialin GUO, Wu ZHONG, Longlong LUO, Zhibing ZHENG, Xinbo ZHOU, Xingzhou LI, Ruiyuan CAO, Shiyong FAN, Dian XIAO, Fei XIE, Wei LI
  • Publication number: 20230293485
    Abstract: The present invention relates to an application of an artemisinin compound in treatment of coronavirus infection. Specifically, the present invention provides an application of the compound, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of medicines. The medicines are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2), and the compound is selected from one or more of artemisinin, arteether, artemether, artemisia ketone, dihydroartemisinin, artesunate, arteannuin B, and artemisinic acid.
    Type: Application
    Filed: July 22, 2021
    Publication date: September 21, 2023
    Inventors: Ruiyuan Cao, Manli Wang, Wei Li, Lei Zhao, Jingjing Yang, Yuexiang Li, Shiyong Fan, Xinbo Zhou, Dian Xiao, Zhihong Hu, Song Li, Wu Zhong
  • Publication number: 20230271970
    Abstract: The present invention relates to the technical field of chemical drug synthesis, and specifically relates to a method for preparing a compound as shown in formula I, comprising: treating the compound as shown in formula VII with an acid to generate the compound as shown in formula I. The method has few synthetic process steps, raw materials which is stable and is easy to prepare, a reaction process which is easy to control, and a high overall yield and purity, and is suitable for industrial preparation.
    Type: Application
    Filed: July 22, 2021
    Publication date: August 31, 2023
    Inventors: Yong Qin, Wu Zhong, Fei Xue, Minjie Zhang, Shiyong Fan, Zhibing Zheng, Song Li
  • Publication number: 20230263811
    Abstract: The present application relates to use of cannabidiol in the preparation of a drug for treating coronavirus infections. The present invention specifically relates to cannabidiol, or a geometric isomer, pharmaceutically acceptable salt, solvate or hydrate thereof, or use of a pharmaceutical composition comprising any one or more of the above components in the preparation of a drug for preventing and/or treating diseases or infections caused by a coronavirus.
    Type: Application
    Filed: July 19, 2021
    Publication date: August 24, 2023
    Inventors: Wu Zhong, Yong Qin, Manli Wang, Ruiyuan Cao, Shiyong Fan, Zhihong Hu, Song Li
  • Publication number: 20230263748
    Abstract: The present invention relates to an application of benflumetol and derivatives thereof in treatment of coronavirus infection, and specifically provides uses of a compound represented by formula A, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of drugs. The drugs are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2).
    Type: Application
    Filed: July 22, 2021
    Publication date: August 24, 2023
    Inventors: Ruiyuan CAO, Manli WANG, Wei LI, Lei ZHAO, Jingjing YANG, Yuexiang LI, Shiyong FAN, Xinbo ZHOU, Dian XIAO, Zhihong HU, Song LI, Wu ZHONG
  • Publication number: 20230218606
    Abstract: Disclosed are hydroxychloroquine or chloroquine, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound, and the use thereof in the treatment of diseases or infections caused by SARS-CoV-2.
    Type: Application
    Filed: June 2, 2020
    Publication date: July 13, 2023
    Inventors: Wu Zhong, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Ruiyuan Cao, Wei Li, Shiyong Fan, Xinbo Zhou, Song Li
  • Publication number: 20230210807
    Abstract: Disclosed are the use of a benzoate compound as shown in formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof and/or a solvate thereof or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound in the prevention and treatment of SARS-CoV-2 infections.
    Type: Application
    Filed: July 15, 2020
    Publication date: July 6, 2023
    Inventors: Wu ZHONG, Ruiyuan CAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Wei LI, Yuexiang LI, Lei ZHAO, Shiyong FAN, Song LI
  • Publication number: 20230119764
    Abstract: A compound represented by the general Formula I, a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or an asymptomatic or symptomatic SARS-CoV-2 infection, and an application of the compound represented by the general Formula I, the geometric isomer thereof, or the pharmaceutically acceptable salt thereof, and/or the solvate thereof, and/or the hydrate thereof in preparation of a product for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or asymptomatic or symptomatic SARS-CoV-2 infection,
    Type: Application
    Filed: July 13, 2020
    Publication date: April 20, 2023
    Inventors: Wu Zhong, Chengfeng Qin, Xinbo Zhou, Yongqiang Deng, Jiqiang Hu, Qingping Jin, Bin Yu, Ruiyuan Cao, Manli Wang, Xiaofeng Li, Nana Zhang, Shiyong Fan, Zhihong Hu, Song Li
  • Publication number: 20230071014
    Abstract: A use of ritonavir, or a geometric isomer, pharmaceutically acceptable salt, solvate, and/or hydrate thereof, and a pharmaceutical composition containing the above compound in treating a SARS-CoV-2 infections.
    Type: Application
    Filed: July 15, 2020
    Publication date: March 9, 2023
    Inventors: Wu Zhong, Zhihong Hu, Gengfu Xiao, Ruiyuan Cao, Manli Wang, Leike Zhang, Wei Li, Shiyong Fan, Song Li
  • Publication number: 20220380402
    Abstract: The present disclosure provides 6-hydrazinoadenosine represented by the general Formula (I) and its derivatives with A2A adenosine receptor agonist activity, and pharmaceutical compositions containing them. The compound and composition can be used as A2A adenosine receptor agonists and used as medicament.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 1, 2022
    Inventors: Wu Zhong, Min Zhang, Xinbo Zhou, Shiyong Fan, Song Li
  • Publication number: 20220378816
    Abstract: 2-Benzylidene hydrazinoadenosine compounds having A2A adenosine receptor agonistic activity, represented by a general Formula (I) and pharmaceutical compositions containing the same. The compounds and compositions can act as A2A adenosine receptor agonist to serve as medicaments.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 1, 2022
    Inventors: Wu Zhong, Min Zhang, Xinbo Zhou, Shiyong Fan, Song Li
  • Publication number: 20220363710
    Abstract: The present application provides a small-molecule compound, represented by general Formula (I), having A2A adenosine receptor antagonistic activity and a pharmaceutical composition containing same. The compound and composition can be used as A2A adenosine receptor antagonistic agents.
    Type: Application
    Filed: June 22, 2020
    Publication date: November 17, 2022
    Inventors: Wu Zhong, Min Zhang, Xinbo Zhou, Shiyong Fan, Song Li
  • Publication number: 20220332750
    Abstract: The present invention relates to a compound represented by Formula I, its pharmaceutically acceptable salt, its stereoisomer, its pharmaceutically acceptable hydrate or solvate, or its pharmaceutically acceptable ester, wherein R is selected from heteroaryl, substituted heteroaryl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, alkyl, and substituted alkyl, wherein the substituted heteroaryl, the substituted aryl, the substituted cycloalkyl and the substituted alkyl are each independently substituted with one or more hydroxyalkylene groups. The compound or its pharmaceutically acceptable salt, its stereoisomer, its pharmaceutically acceptable hydrate or solvate, its pharmaceutically acceptable ester of the present invention has agonistic activity on A2A adenosine receptor and can improve the permeability of blood-brain barrier to promote the delivery of drug across blood-brain barrier, and can also prevent or treat a disease associated with A2A adenosine receptor agonistic activity.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 20, 2022
    Inventors: Wu Zhong, Min Zhang, Xinbo Zhou, Shiyong Fan, Song Li
  • Publication number: 20220220106
    Abstract: Provided are quinoline derivative compounds of Formulae (I), (II) and (III) with an inhibitory effect on mTOR and applications of their pharmaceutically acceptable salts, their stereoisomers, their hydrates or their solvates in preparation of medicine for preventing and/or treating diseases caused by enteroviruses.
    Type: Application
    Filed: April 24, 2020
    Publication date: July 14, 2022
    Inventors: Wu ZHONG, Tianlong HAO, Ruiyuan CAO, Tong CHENG, Yuexiang LI, Shiyong FAN, Wei LI, Shixu WANG, Ningshao XIA, Song LI
  • Publication number: 20220193039
    Abstract: Related is application of 2,4,5-trisubstituted 1,2,4-triazolones in antiviral therapy, particularly related to use of a compound of formula I in the preparation a medicament, wherein the medicament is used to prevent and/or treat a disease associated with a virus.
    Type: Application
    Filed: July 15, 2021
    Publication date: June 23, 2022
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Xinbo ZHOU, Ruiyuan CAO, Dian XIAO, Manli WANG, Shiyong FAN, Zhihong HU, Song LI
  • Publication number: 20220105077
    Abstract: Related is application of 2,4,5-trisubstituted 1,2,4-triazolones in antiviral therapy, particularly related to use of a compound of formula I in the preparation a medicament, wherein the medicament is used to prevent and/or treat a disease associated with a virus.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Xinbo ZHOU, Ruiyuan CAO, Dian XIAO, Manli WANG, Shiyong FAN, Zhihong HU, Song LI
  • Publication number: 20210346411
    Abstract: The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Wei LI, Yuexiang LI, Lei ZHAO, Shiyong FAN, Song LI
  • Publication number: 20210261505
    Abstract: Provided are a linker represented by Formula I or I?, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.
    Type: Application
    Filed: August 15, 2019
    Publication date: August 26, 2021
    Inventors: Xinbo ZHOU, Yanming WANG, Shiyong FAN, Song LI, Wu ZHONG, Junhai XIAO, Zhibing ZHENG, Xingzhou LI, Dian XIAO, Yunde XIE, Xiaokui WANG, Ruiyuan CAO
  • Publication number: 20210220377
    Abstract: The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 22, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan Cao, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Wei Li, Yuexiang Li, Lei Zhao, Shiyong Fan, Song Li
  • Publication number: 20210205464
    Abstract: The present application relates to a linker containing arylnitro, an antibody-drug conjugate the linker and use of the linker, as well as a pharmaceutical composition comprising the antibody-drug conjugate and use of the antibody-drug conjugate for treatment and/or prevention of a disease.
    Type: Application
    Filed: August 28, 2019
    Publication date: July 8, 2021
    Inventors: Xinbo ZHOU, Yanming WANG, Song LI, Wu ZHONG, Shiyong FAN, Dian XIAO, Junhai XIAO, Zhibing ZHENG, Xingzhou LI, Yunde XIE, Ruiyuan CAO, Xiaokui WANG